Palisade Bio Transforms GI-Focused Pipeline Through

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing...

Related Keywords

Canada ,United States ,Canadian ,Giiant Pharma ,Christophe Mellon ,Jenene Thomas ,Company Annual Report On Form ,Palisade Bio Inc ,Company Quarterly Report On Form ,Colitis Foundation ,Exchange Commission ,Nasdaq ,Giiant Pharma Inc ,Chief Executive Officer ,Palisade Bio ,Chief Executive ,Precision Delivery ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Nasdaq Pali ,Nc ,Iopharmaceutical Company ,I Focused Pipeline ,Orldwide Licensing Agreement ,